Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HIPK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HIPK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HIPK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HIPK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HIPK2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HIPK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HIPK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HIPK2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HIPK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HIPK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003109813 | Lung | AIS | stress-activated protein kinase signaling cascade | 51/1849 | 247/18723 | 2.69e-07 | 2.37e-05 | 51 |
GO:001810512 | Lung | AIS | peptidyl-serine phosphorylation | 60/1849 | 315/18723 | 4.75e-07 | 3.64e-05 | 60 |
GO:000725413 | Lung | AIS | JNK cascade | 38/1849 | 167/18723 | 7.27e-07 | 5.36e-05 | 38 |
GO:007155912 | Lung | AIS | response to transforming growth factor beta | 51/1849 | 256/18723 | 8.45e-07 | 6.08e-05 | 51 |
GO:005140313 | Lung | AIS | stress-activated MAPK cascade | 48/1849 | 239/18723 | 1.38e-06 | 8.75e-05 | 48 |
GO:001820912 | Lung | AIS | peptidyl-serine modification | 61/1849 | 338/18723 | 2.49e-06 | 1.41e-04 | 61 |
GO:007233213 | Lung | AIS | intrinsic apoptotic signaling pathway by p53 class mediator | 22/1849 | 76/18723 | 2.53e-06 | 1.42e-04 | 22 |
GO:001821012 | Lung | AIS | peptidyl-threonine modification | 30/1849 | 125/18723 | 3.29e-06 | 1.74e-04 | 30 |
GO:003133013 | Lung | AIS | negative regulation of cellular catabolic process | 50/1849 | 262/18723 | 3.94e-06 | 2.05e-04 | 50 |
GO:004277011 | Lung | AIS | signal transduction in response to DNA damage | 37/1849 | 172/18723 | 4.17e-06 | 2.13e-04 | 37 |
GO:007156012 | Lung | AIS | cellular response to transforming growth factor beta stimulus | 48/1849 | 250/18723 | 5.13e-06 | 2.47e-04 | 48 |
GO:007030213 | Lung | AIS | regulation of stress-activated protein kinase signaling cascade | 40/1849 | 195/18723 | 5.96e-06 | 2.78e-04 | 40 |
GO:001810712 | Lung | AIS | peptidyl-threonine phosphorylation | 28/1849 | 116/18723 | 6.14e-06 | 2.82e-04 | 28 |
GO:003410113 | Lung | AIS | erythrocyte homeostasis | 30/1849 | 129/18723 | 6.51e-06 | 2.92e-04 | 30 |
GO:003021813 | Lung | AIS | erythrocyte differentiation | 28/1849 | 120/18723 | 1.22e-05 | 4.71e-04 | 28 |
GO:004632812 | Lung | AIS | regulation of JNK cascade | 30/1849 | 133/18723 | 1.24e-05 | 4.75e-04 | 30 |
GO:000717912 | Lung | AIS | transforming growth factor beta receptor signaling pathway | 39/1849 | 198/18723 | 2.08e-05 | 7.12e-04 | 39 |
GO:003287213 | Lung | AIS | regulation of stress-activated MAPK cascade | 38/1849 | 192/18723 | 2.36e-05 | 7.81e-04 | 38 |
GO:005109813 | Lung | AIS | regulation of binding | 61/1849 | 363/18723 | 2.48e-05 | 8.06e-04 | 61 |
GO:003009913 | Lung | AIS | myeloid cell differentiation | 63/1849 | 381/18723 | 3.05e-05 | 9.70e-04 | 63 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HIPK2 | SNV | Missense_Mutation | | c.1945N>C | p.Asp649His | p.D649H | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
HIPK2 | SNV | Missense_Mutation | rs764542823 | c.350G>A | p.Arg117Gln | p.R117Q | Q9H2X6 | protein_coding | tolerated(0.2) | probably_damaging(0.978) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HIPK2 | SNV | Missense_Mutation | novel | c.2665N>G | p.Thr889Ala | p.T889A | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
HIPK2 | SNV | Missense_Mutation | | c.1477N>A | p.Glu493Lys | p.E493K | Q9H2X6 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD |
HIPK2 | SNV | Missense_Mutation | | c.2108C>G | p.Ala703Gly | p.A703G | Q9H2X6 | protein_coding | deleterious(0) | benign(0.108) | TCGA-AR-A0U2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | PD |
HIPK2 | SNV | Missense_Mutation | rs747709692 | c.280N>A | p.Val94Met | p.V94M | Q9H2X6 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AR-A2LN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
HIPK2 | SNV | Missense_Mutation | | c.47N>G | p.Ser16Cys | p.S16C | Q9H2X6 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-B6-A3ZX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
HIPK2 | SNV | Missense_Mutation | | c.2220N>C | p.Glu740Asp | p.E740D | Q9H2X6 | protein_coding | tolerated(0.99) | benign(0.001) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
HIPK2 | SNV | Missense_Mutation | rs773782325 | c.140N>C | p.His47Pro | p.H47P | Q9H2X6 | protein_coding | tolerated(0.1) | possibly_damaging(0.71) | TCGA-C8-A1HO-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
HIPK2 | SNV | Missense_Mutation | rs773782325 | c.140N>C | p.His47Pro | p.H47P | Q9H2X6 | protein_coding | tolerated(0.1) | possibly_damaging(0.71) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | inhibitor | 249565808 | | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | TAMATINIB | R-406 | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PI-103 | PI-103 | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | GSK-269962A | GSK-269962A | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | CENISERTIB | CENISERTIB | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | BAY-613606 | CHEMBL541400 | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | ILORASERTIB | ILORASERTIB | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PF-562271 | PF-00562271 | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | PHA-767491 | CHEMBL225519 | |
28996 | HIPK2 | TYROSINE KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME, ENZYME | | SP-600125 | SP-600125 | |